PBAC's latest decision on Pneumococcal polysaccharide conjugate vaccine: Recommended with restriction (2009). Considered for For immunisation of all Australian infants and children from the age of eight weeks to two years of age against disease caused by Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (including invasive disease, pneumonia, and acute otitis media).
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2009
Submissions
1
2009 → 2009
Eligible population
All Australian infants and children from the age of eight weeks to two years of age
Therapy area
Immunology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
ELISA with 22F pre-adsorption for assessment of immunogenicity, Opsonophagocytic assay (OPA), Protein D measured using ELISA
Key trials
Trials 001, 003, 011, 012, Trials 007 and 017: extensions of Trials 001 and 011, respectively